Table 4 Multivariate logistic regression analysis on the incidence of abnormal serum ALT level considering CYP2B6 SNVs, haplotypes, estimated phenotypes and non-genetic factors (age, sex).

From: Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma

Model

Variables

Increased serum ALT levels

Coefficient B (SE)

Exp ß

P

SNVs, non-genetic factorsa

Constant

− 24.39 (40,192)

0

1

g.-82T>C (rs34223104)

22.33 (40,192)

4,996,498,070

1

g.15631G>T (rs3745274)

0.27 (1.37)

1.31

0.84

Model 1

g.18053A>G (rs2279343)

1 (1.39)

0.14

0.16

g.25505C>T (rs3211371)

− 1.39 (0.89)

0.24

0.11

Sex

− 0.47 (0.70)

0.95

0.94

Age

0.02 (0.10)

1.02

0.80

Haplotypes, non-genetic factorsb,d

Constant

25.60 (79,461)

1.31E+11

1

CYP2B6*4 (g.-82T/15631G/18053G/25505C)

− 0.69 (1.09)

0.49

0.76

CYP2B6*5 (g.-82T/15631G/18053A/25505T)

− 1.22 (0.86)

0.29

0.16

Model 2 (corrected P ≤ 0.01)

CYP2B6*6 (g.-82T/15631T/18053G/25505T)

− 1.97 (0.74)

0.13

0.008

CYP2B6*22 (g.-82C/15631G/18053A/25505C)

− 23.31 (79,461)

7.49E−11

1.00

Sex

0.21 (0.70)

1.23

0.76

Age

0.64 (0.71)

1.89

0.37

Estimated phenotype, non-genetic factorsc

Constant

0.60 (0.75)

1.83

0.42

Poor/intermediate

− 1.56 (0.67)

0.21

0.02

Model 3 (corrected P ≤ 0.02)

Sex

0.11 (0.65)

1.12

0.86

Age

0.60 (0.68)

1.82

0.38

  1. Significant values are in bold.
  2. aAIC: 37.71, BIC: 50.66 for model 1, bAIC: 40.89, BIC: 53.85 for model 2, cAIC: 25.59, BIC: 32.99 for model 3; dPost-hoc power: 94.1%.